Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 307

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 307
---

         
        $
        36,632

        $
        32,449

        Personnel

        19,701

        17,276

        Chemistry, manufacturing and control

        11,350

        14,865

        Preclinical studies and activities

        1,629

        1,267

        Consultants and other costs

        2,172

        1,972

        Total research and development expenses
         
        $
        71,484

        $
        67,829

      General and Administrative

        Year Ended December 31,

        2024

        2023

        (in thousands)

        Personnel
         
        $
        11,367

        $
        10,294

        Professional services

        4,847

        4,469

        Consultants and other costs

        7,479

        8,851

        Total general and administrative expenses
         
        $
        23,693

        $
        23,614

16. Subsequent Events We have evaluated subsequent events through the date on which the consolidated financial statements were issued. The Company has concluded that no subsequent events have occurred that require disclosure to the consolidated financial statements. 

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

165

Item 9A. Controls and Procedures.

Management’s Evaluation of our Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance